New Oral Treatment for IBS-D Launched
Viberzi is a first-in-class mu-opioid receptor agonist; delta opioid receptor antagonist, and kappa opioid receptor agonist. It was approved by the Food and Drug Administration (FDA) in May 2015. It acts locally in the gastrointestinal tract to treat the symptoms of IBS-D while reducing the incidence of constipation that can occur with unopposed mu-opioid receptor agonists.
RELATED: Irritable Bowel Syndrome Treatments Chart
In November, the Drug Enforcement Agency (DEA) published its Final Rule classifying Viberzi as a Schedule IV substance.
Viberzi is available as 75mg and 100mg strength tablets in 60-count bottles.
For more information call (800) 678-1605 or visit Viberzi.com.